TY - JOUR
T1 - DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX
T2 - A National Registry Analysis
AU - Coylewright, Megan
AU - Holmes, David R.
AU - Kapadia, Samir R.
AU - Hsu, Jonathan C.
AU - Gibson, Douglas N.
AU - Freeman, James V.
AU - Yeh, Robert W.
AU - Piccini, Jonathan P.
AU - Price, Matthew J.
AU - Allocco, Dominic J.
AU - Nair, Devi G.
N1 - Publisher Copyright:
© 2023
PY - 2023/11/27
Y1 - 2023/11/27
N2 - Background: Left atrial appendage occlusion (LAAO) is an approved alternative for stroke prevention in atrial fibrillation for patients with an “appropriate rationale” to avoid long-term oral anticoagulation (OAC). Many patients undergoing LAAO are at high risk of bleeding. Objectives: This study sought to investigate whether dual antiplatelet therapy (DAPT) is a safe alternative to OAC (direct oral anticoagulation [DOAC] or warfarin) with aspirin after LAAO. Methods: Using National Cardiovascular Data Registry LAAO registry data, patients undergoing Watchman FLX (Boston Scientific) implantation (August 5, 2020-September 30, 2021) were included in 1:1 propensity-matched analyses comparing discharge medication regimens (DAPT, DOAC/aspirin, or warfarin/aspirin). A composite endpoint (death, stroke, major bleeding, and systemic embolism), its components, and device-related thrombus between discharge and 45 days were evaluated. Results: In 49,968 patients implanted with the Watchman FLX during the study period, the mean age was 77 years, and 40% were women. Postimplant DOAC/aspirin was prescribed in 24,497 patients, warfarin/aspirin in 3,913, and DAPT in 4,155. DAPT patients had more comorbid conditions than patients receiving OAC/aspirin. After propensity score matching, the 45-day composite endpoint rates were similar among the groups (DAPT = 3.44% vs DOAC/aspirin: 4.06%; P = 0.13 and DAPT = 3.23% vs warfarin/aspirin: 3.08%; P = 0.75). Death, stroke, and device-related thrombus were also similar; major bleeding was slightly increased in DOAC/aspirin patients (DAPT = 2.48% vs DOAC/aspirin = 3.25%; P = 0.04 and DAPT = 2.25% vs warfarin/aspirin = 2.22%; P = 0.93). Conclusions: In a large registry, DAPT had a similar safety profile compared with current Food and Drug Administration–approved postimplant drug regimens of OAC with aspirin following LAAO with the Watchman FLX. Shared decision making for nonpharmacologic stroke prevention should include a discussion of postprocedure medical therapy options.
AB - Background: Left atrial appendage occlusion (LAAO) is an approved alternative for stroke prevention in atrial fibrillation for patients with an “appropriate rationale” to avoid long-term oral anticoagulation (OAC). Many patients undergoing LAAO are at high risk of bleeding. Objectives: This study sought to investigate whether dual antiplatelet therapy (DAPT) is a safe alternative to OAC (direct oral anticoagulation [DOAC] or warfarin) with aspirin after LAAO. Methods: Using National Cardiovascular Data Registry LAAO registry data, patients undergoing Watchman FLX (Boston Scientific) implantation (August 5, 2020-September 30, 2021) were included in 1:1 propensity-matched analyses comparing discharge medication regimens (DAPT, DOAC/aspirin, or warfarin/aspirin). A composite endpoint (death, stroke, major bleeding, and systemic embolism), its components, and device-related thrombus between discharge and 45 days were evaluated. Results: In 49,968 patients implanted with the Watchman FLX during the study period, the mean age was 77 years, and 40% were women. Postimplant DOAC/aspirin was prescribed in 24,497 patients, warfarin/aspirin in 3,913, and DAPT in 4,155. DAPT patients had more comorbid conditions than patients receiving OAC/aspirin. After propensity score matching, the 45-day composite endpoint rates were similar among the groups (DAPT = 3.44% vs DOAC/aspirin: 4.06%; P = 0.13 and DAPT = 3.23% vs warfarin/aspirin: 3.08%; P = 0.75). Death, stroke, and device-related thrombus were also similar; major bleeding was slightly increased in DOAC/aspirin patients (DAPT = 2.48% vs DOAC/aspirin = 3.25%; P = 0.04 and DAPT = 2.25% vs warfarin/aspirin = 2.22%; P = 0.93). Conclusions: In a large registry, DAPT had a similar safety profile compared with current Food and Drug Administration–approved postimplant drug regimens of OAC with aspirin following LAAO with the Watchman FLX. Shared decision making for nonpharmacologic stroke prevention should include a discussion of postprocedure medical therapy options.
KW - anticoagulation
KW - antiplatelet
KW - bleeding
KW - left atrial appendage occlusion
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85177042525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85177042525&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2023.08.013
DO - 10.1016/j.jcin.2023.08.013
M3 - Article
C2 - 37943200
AN - SCOPUS:85177042525
SN - 1936-8798
VL - 16
SP - 2708
EP - 2718
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 22
ER -